L’Oreal Settles Pending Patent Infringement Litigation With NeoStrata

TriStrata Technology Inc. (TTI) and L’Oreal USA have settled patent infringement litigation currently pending between the two companies in the U.S. District Court for the District of Delaware. The settlement resolves litigation concerning TTI’s claim of patent infringement arising from L’Oreal’s alleged use of certain patents owned by TTI relating to the use of alpha hydroxy acids (AHAs) for the reduction of human skin wrinkles and the alleviation of the signs of dermatological aging. The settlement consists of a license agreement, the financial terms of which are confidential.

TTI is a wholly owned subsidiary of NeoStrata Company Inc., founded by Drs. Ruey Yu, O.M.D., Ph.D. and Eugene Van Scott, M.D. who are the inventors of more than 80 patents relating to AHA technology.

L’Oreal is the most recent defendant to settle the patent infringement litigation with TTI. Previous settlements have been reached with Beiersdorf, Chanel and Lenier Health Products Inc. The litigation is still pending and proceeding against Clarins Inc., Murad Skin Research Laboratories Inc., Howard Murad, M.D., and Neoteric Inc.

TTI was represented in the settlement by Kevin M. McGovern, Esq. and Brian T. Foley, Esq. of McGovern & Associates, Greenwich, CT. L’Oreal was represented in the settlement by John Sullivan, Esq., L’Oreal USA’s General Council, Bruce Genderson, Esq. of Williams & Connelly and Jean Paul Levelleye, Esq. of Oblon, Spivak, McClelland, Maier & Neustadt, P.C.

Richard H. Wildnauer, Ph.D., president of TTI’s parent NeoStrata, remarked: “We are delighted to have a market leader and innovator such as L’Oreal join the growing list of TTI’s licensees on terms that we believe are mutually beneficial to both companies.”

L’Oreal joins the growing list of companies that have licensed certain aspects of TTI’s AHA technology including Allergan, Avon, Bristol-Myers Squibb, Beiersdorf, Canderm Pharma, Chanel, Cognis, Collagen Corporation, Conopco, a subsidiary of Unilever (Chesebrough-Ponds and Elizabeth Arden), Erno Lazlo, Genesis Pharmaceutical Inc., IGI Inc., Merz Pharmaceuticals, M.D.F. Acquisitions Corporation, Nucelle Inc., Summers Labs, Stratus Pharmaceuticals and Stiefel.